Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.

Mondaca S, Margolis M, Sanchez-Vega F, Jonsson P, Riches JC, Ku GY, Hechtman JF, Tuvy Y, Berger MF, Shah MA, Kelsen DP, Ilson DH, Yu K, Goldberg Z, Epstein AS, Desai A, Chung V, Chou JF, Capanu M, Solit DB, Schultz N, Janjigian YY.

Gastric Cancer. 2018 Aug 7. doi: 10.1007/s10120-018-0861-7. [Epub ahead of print]

PMID:
30088161
2.

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.

Lowery MA, Wong W, Jordan EJ, Lee JW, Kemel Y, Vijai J, Mandelker D, Zehir A, Capanu M, Salo-Mullen E, Arnold AG, Yu KH, Varghese AM, Kelsen DP, Brenner R, Kaufmann E, Ravichandran V, Mukherjee S, Berger MF, Hyman DM, Klimstra DS, Abou-Alfa GK, Tjan C, Covington C, Maynard H, Allen PJ, Askan G, Leach SD, Iacobuzio-Donahue CA, Robson ME, Offit K, Stadler ZK, O'Reilly EM.

J Natl Cancer Inst. 2018 Feb 28. doi: 10.1093/jnci/djy024. [Epub ahead of print]

PMID:
29506128
3.

In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of 18F-(2S,4R)-4-Fluoroglutamine.

Dunphy MPS, Harding JJ, Venneti S, Zhang H, Burnazi EM, Bromberg J, Omuro AM, Hsieh JJ, Mellinghoff IK, Staton K, Pressl C, Beattie BJ, Zanzonico PB, Gerecitano JF, Kelsen DP, Weber W, Lyashchenko SK, Kung HF, Lewis JS.

Radiology. 2018 May;287(2):667-675. doi: 10.1148/radiol.2017162610. Epub 2018 Jan 31.

PMID:
29388903
4.

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations.

Hu ZI, Shia J, Stadler ZK, Varghese AM, Capanu M, Salo-Mullen E, Lowery MA, Diaz LA Jr, Mandelker D, Yu KH, Zervoudakis A, Kelsen DP, Iacobuzio-Donahue CA, Klimstra DS, Saltz LB, Sahin IH, O'Reilly EM.

Clin Cancer Res. 2018 Mar 15;24(6):1326-1336. doi: 10.1158/1078-0432.CCR-17-3099. Epub 2018 Jan 24.

PMID:
29367431
5.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.

O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.

Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.

PMID:
29338080
6.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.

Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.

PMID:
29223478
7.

Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.

Janjigian YY, Sanchez-Vega F, Jonsson P, Chatila WK, Hechtman JF, Ku GY, Riches JC, Tuvy Y, Kundra R, Bouvier N, Vakiani E, Gao J, Heins ZJ, Gross BE, Kelsen DP, Zhang L, Strong VE, Schattner M, Gerdes H, Coit DG, Bains M, Stadler ZK, Rusch VW, Jones DR, Molena D, Shia J, Robson ME, Capanu M, Middha S, Zehir A, Hyman DM, Scaltriti M, Ladanyi M, Rosen N, Ilson DH, Berger MF, Tang L, Taylor BS, Solit DB, Schultz N.

Cancer Discov. 2018 Jan;8(1):49-58. doi: 10.1158/2159-8290.CD-17-0787. Epub 2017 Nov 9.

PMID:
29122777
8.

The newly proposed clinical and post-neoadjuvant treatment staging classifications for gastric adenocarcinoma for the American Joint Committee on Cancer (AJCC) staging.

In H, Ravetch E, Langdon-Embry M, Palis B, Ajani JA, Hofstetter WL, Kelsen DP, Sano T.

Gastric Cancer. 2018 Jan;21(1):1-9. doi: 10.1007/s10120-017-0765-y. Epub 2017 Sep 25.

PMID:
28948368
9.

A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.

Lowery MA, Yu KH, Kelsen DP, Harding JJ, Bomalaski JS, Glassman DC, Covington CM, Brenner R, Hollywood E, Barba A, Johnston A, Liu KC, Feng X, Capanu M, Abou-Alfa GK, O'Reilly EM.

Cancer. 2017 Dec 1;123(23):4556-4565. doi: 10.1002/cncr.30897. Epub 2017 Aug 18.

PMID:
28832976
10.

Cancer of the esophagus and esophagogastric junction-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual.

Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH.

CA Cancer J Clin. 2017 Jul 8;67(4):304-317. doi: 10.3322/caac.21399. Epub 2017 May 26.

11.

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.

Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.

Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.

12.

Recommendations for pathologic staging (pTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.

Rice TW, Ishwaran H, Hofstetter WL, Kelsen DP, Apperson-Hansen C, Blackstone EH; Worldwide Esophageal Cancer Collaboration Investigators.

Dis Esophagus. 2016 Nov;29(8):897-905. doi: 10.1111/dote.12533.

13.

Recommendations for clinical staging (cTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.

Rice TW, Ishwaran H, Blackstone EH, Hofstetter WL, Kelsen DP, Apperson-Hansen C; Worldwide Esophageal Cancer Collaboration Investigators.

Dis Esophagus. 2016 Nov;29(8):913-919. doi: 10.1111/dote.12540.

14.

Recommendations for neoadjuvant pathologic staging (ypTNM) of cancer of the esophagus and esophagogastric junction for the 8th edition AJCC/UICC staging manuals.

Rice TW, Ishwaran H, Kelsen DP, Hofstetter WL, Apperson-Hansen C, Blackstone EH; Worldwide Esophageal Cancer Collaboration Investigators.

Dis Esophagus. 2016 Nov;29(8):906-912. doi: 10.1111/dote.12538.

15.

Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience.

Won E, Shah MA, Schöder H, Strong VE, Coit DG, Brennan MF, Kelsen DP, Janjigian YY, Tang LH, Capanu M, Rizk NP, Allen PJ, Bains MS, Ilson DH.

J Gastrointest Oncol. 2016 Aug;7(4):506-14. doi: 10.21037/jgo.2016.06.01.

16.

Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma.

Ku GY, Kriplani A, Janjigian YY, Kelsen DP, Rusch VW, Bains M, Chou J, Capanu M, Wu AJ, Goodman KA, Ilson DH.

Cancer. 2016 Jul 1;122(13):2083-90. doi: 10.1002/cncr.30028. Epub 2016 May 6.

17.

Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.

Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.

Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26. Review.

18.

Identification of germline genetic mutations in patients with pancreatic cancer.

Salo-Mullen EE, O'Reilly EM, Kelsen DP, Ashraf AM, Lowery MA, Yu KH, Reidy DL, Epstein AS, Lincoln A, Saldia A, Jacobs LM, Rau-Murthy R, Zhang L, Kurtz RC, Saltz L, Offit K, Robson ME, Stadler ZK.

Cancer. 2015 Dec 15;121(24):4382-8. doi: 10.1002/cncr.29664. Epub 2015 Oct 6.

19.

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, Su YB, Ocean A, Capanu M, Mehrotra B, Ritch P, Henderson C, Kelsen DP.

J Clin Oncol. 2015 Nov 20;33(33):3874-9.

PMID:
26438119
20.

Treatment, Outcomes, and Clinical Trial Participation in Elderly Patients With Metastatic Pancreas Adenocarcinoma.

Li D, Capanu M, Yu KH, Lowery MA, Kelsen DP, O'Reilly EM.

Clin Colorectal Cancer. 2015 Dec;14(4):269-76.e1. doi: 10.1016/j.clcc.2015.05.005. Epub 2015 May 22.

21.

Liver-directed conversion therapy in metastatic colon cancer.

Snyder A, Kemeny N, Shamseddine A, Al-Olayan A, El-Merhi F, Kelsen DP, Jamali F, Sidani M, Mukherji D, El-Naghy M, O'Reilly EM, Saltz LB, Abou-Alfa GK.

J Gastrointest Oncol. 2015 Jun;6(3):322-8. doi: 10.3978/j.issn.2078-6891.2015.006. No abstract available.

22.

Combined modality therapy in pancreatic adenocarcinoma: review and updates on a controversial issue.

Cavalcante L, Kelsen DP, Yu KH.

Curr Pharm Des. 2014;20(42):6697-701. Review.

PMID:
25341941
23.

A woman with metastatic pancreatic neuroendocrine tumor.

Shoushtari AN, Covey AM, Zaatari G, Shamseddine A, Epstein AS, Haydar A, Naghy M, Mukherji D, Kelsen DP, Abou-Alfa GK, O'Reilly EM.

Gastrointest Cancer Res. 2014 Jan;7(1):27-32. No abstract available.

24.

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park DJ, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27.

PMID:
24370903
25.

A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.

Abou-Alfa GK, Capanu M, O'Reilly EM, Ma J, Chou JF, Gansukh B, Shia J, Kalin M, Katz S, Abad L, Reidy-Lagunes DL, Kelsen DP, Chen HX, Saltz LB.

J Hepatol. 2014 Feb;60(2):319-24. doi: 10.1016/j.jhep.2013.09.008. Epub 2013 Sep 14.

26.

Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.

Gerber N, Ilson DH, Wu AJ, Janjigian YY, Kelsen DP, Zheng J, Zhang Z, Bains MS, Rizk N, Rusch VW, Goodman KA.

Dis Esophagus. 2014 Apr;27(3):235-41. doi: 10.1111/dote.12082. Epub 2013 Jun 24.

PMID:
23796070
27.

A randomized controlled trial of a cardiopulmonary resuscitation video in advance care planning for progressive pancreas and hepatobiliary cancer patients.

Epstein AS, Volandes AE, Chen LY, Gary KA, Li Y, Agre P, Levin TT, Reidy DL, Meng RD, Segal NH, Yu KH, Abou-Alfa GK, Janjigian YY, Kelsen DP, O'Reilly EM.

J Palliat Med. 2013 Jun;16(6):623-31. doi: 10.1089/jpm.2012.0524. Epub 2013 Apr 22.

28.

A young woman with liver cancer.

Ang CS, Do RK, Shamseddine A, O'Reilly EM, Haydar A, Al-Olayan A, Faraj W, Boulos F, Naghy M, Makanjoula D, Farran H, Sibai H, Wehbe D, Kelsen DP, Abou-Alfa GK.

Gastrointest Cancer Res. 2013 Jan;6(1):17-21. No abstract available.

29.

Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH.

Am J Clin Oncol. 2014 Apr;37(2):126-30. doi: 10.1097/COC.0b013e318271b14f.

PMID:
23211227
30.

Neoadjuvant Therapy in Clinical Stage II Pancreatic Adenocarcinoma.

Snyder A, Allen P, Shamseddine A, Haydar A, Eloubeidi M, Faraj W, Khalife M, Temraz S, El-Olayan A, Kelsen DP, El-Merhi F, Naghy M, Saltz LB, Abou-Alfa GK, O'Reilly EM.

Gastrointest Cancer Res. 2012 Sep;5(5):169-73. No abstract available.

31.

Genomic dysregulation in gastric tumors.

Janjigian YY, Kelsen DP.

J Surg Oncol. 2013 Mar;107(3):237-42. doi: 10.1002/jso.23263. Epub 2012 Oct 5. Review.

PMID:
23042588
32.

A 72-year-old man with duodenal adenocarcinoma.

Tamraz S, Shamseddine A, Shah M, El-Oubeidi M, Zaatari G, Geara F, Lowery MA, O'Reilly EM, Al-Kutoubi A, Faraj W, Kelsen DP, Abou-Alfa GK.

Gastrointest Cancer Res. 2012 May;5(3):93-6. No abstract available.

33.

A case of advanced gastric cancer.

Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O'Reilly EM, Geara F, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK.

Gastrointest Cancer Res. 2012 Mar;5(2):59-63. No abstract available.

34.

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Janjigian YY, Werner D, Pauligk C, Steinmetz K, Kelsen DP, Jäger E, Altmannsberger HM, Robinson E, Tafe LJ, Tang LH, Shah MA, Al-Batran SE.

Ann Oncol. 2012 Oct;23(10):2656-62. Epub 2012 Jun 11.

PMID:
22689179
35.

A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.

Smyth E, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit DG, Shah MA.

Cancer. 2012 Nov 15;118(22):5481-8. doi: 10.1002/cncr.27550. Epub 2012 May 1.

36.

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M.

Cancer. 2012 Jun 1;118(11):2820-7. doi: 10.1002/cncr.26591. Epub 2011 Oct 11.

37.

Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer.

Epstein AS, Soff GA, Capanu M, Crosbie C, Shah MA, Kelsen DP, Denton B, Gardos S, O'Reilly EM.

Cancer. 2012 Jun 15;118(12):3053-61. doi: 10.1002/cncr.26600. Epub 2011 Oct 11.

38.

An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.

Lowery MA, Kelsen DP, Stadler ZK, Yu KH, Janjigian YY, Ludwig E, D'Adamo DR, Salo-Mullen E, Robson ME, Allen PJ, Kurtz RC, O'Reilly EM.

Oncologist. 2011;16(10):1397-402. doi: 10.1634/theoncologist.2011-0185. Epub 2011 Sep 20.

39.

A man with Klinefelter's syndrome and new abdominal distension: a discussion of evaluation and management.

Postow M, Shah MA, Lowery M, Shamseddine A, El-Kutoubi A, Al Olayan A, Naghy M, Ang C, Tamraz S, Jazieh AR, O'Reilly EM, Kelsen DP, Abou-Alfa GK.

J Gastrointest Cancer. 2012 Jun;43(2):314-8. doi: 10.1007/s12029-011-9294-9. No abstract available.

PMID:
21660410
40.

Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma.

Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA.

Br J Cancer. 2011 Jun 7;104(12):1840-7. doi: 10.1038/bjc.2011.175. Epub 2011 May 24.

41.

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer.

Stadler ZK, Salo-Mullen E, Patil SM, Pietanza MC, Vijai J, Saloustros E, Hansen NA, Kauff ND, Kurtz RC, Kelsen DP, Offit K, Robson ME.

Cancer. 2012 Jan 15;118(2):493-9. doi: 10.1002/cncr.26191. Epub 2011 May 19.

42.

Molecular classification of gastric cancer: a new paradigm.

Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP.

Clin Cancer Res. 2011 May 1;17(9):2693-701. doi: 10.1158/1078-0432.CCR-10-2203. Epub 2011 Mar 23.

43.

MET expression and amplification in patients with localized gastric cancer.

Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1021-7. doi: 10.1158/1055-9965.EPI-10-1080. Epub 2011 Mar 10.

44.

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP.

J Clin Oncol. 2011 Mar 1;29(7):868-74. doi: 10.1200/JCO.2010.32.0770. Epub 2010 Dec 28.

45.

Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine.

Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M, Gansukh B, Jacobs G, Levin A, Neville D, Kelsen DP, O'Reilly EM.

Am J Clin Oncol. 2011 Jun;34(3):321-5. doi: 10.1097/COC.0b013e3181e84b1f.

PMID:
20686403
46.

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP.

Invest New Drugs. 2011 Dec;29(6):1475-81. doi: 10.1007/s10637-010-9474-7. Epub 2010 Jun 25.

PMID:
20574790
47.

Risk factors for developing a new venous thromboembolism in ambulatory patients with non-hematologic malignancies and impact on survival for gastroesophageal malignancies.

Shah MA, Capanu M, Soff G, Asmis T, Kelsen DP.

J Thromb Haemost. 2010 Aug;8(8):1702-9. doi: 10.1111/j.1538-7836.2010.03948.x. Epub 2010 Jun 14.

48.
49.

Advanced gastric cancer--slow but steady progress.

Power DG, Kelsen DP, Shah MA.

Cancer Treat Rev. 2010 Aug;36(5):384-92. doi: 10.1016/j.ctrv.2010.01.005. Epub 2010 Feb 21. Review.

PMID:
20176443
50.

A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.

Carvajal RD, Tse A, Shah MA, Lefkowitz RA, Gonen M, Gilman-Rosen L, Kortmansky J, Kelsen DP, Schwartz GK, O'Reilly EM.

Pancreatology. 2009;9(4):404-9. doi: 10.1159/000187135. Epub 2009 May 19.

Supplemental Content

Loading ...
Support Center